Needham analyst Matthew Shea has reiterated their bullish stance on TOI stock, giving a Buy rating on March 9.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Matthew Shea has given his Buy rating due to a combination of factors tied to The Oncology Institute’s improving fundamentals and valuation. He highlights that the company exited FY25 with its first quarter of positive adjusted EBITDA, views the FY26 guidance as deliberately cautious, and believes accelerating capitated contract demand and growth in the new Florida pharmacy can drive upside to current expectations.
He also emphasizes that the market is not fully recognizing the increased predictability from delegated contracts, the risk-mitigating nature of the pharmacy segment, and management’s longer-term goal of achieving mid-single-digit EBITDA margins by 2028. In his view, these elements together create an attractive risk‑reward profile, supporting a Buy rating and a $5 price target on this undervalued value-based care platform.
In another report released on March 9, BTIG also maintained a Buy rating on the stock with a $7.00 price target.